Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.64 |
| ▸ | MAG | P20916 | 8/20 | 0.54 |
| ▸ | SELL | P14151 | 2/20 | 0.52 |
| ▸ | SELP | P16109 | 2/20 | 0.52 |
| ▸ | SELE | P16581 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29361332 | 1.00 | SIGLEC7 (0.64) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL29693389 | 1.00 | SIGLEC7 (0.64) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL23087055 | 1.00 | SIGLEC7 (0.64) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL29361920 | 0.97 | SIGLEC7 (0.60) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL29361675 | 0.97 | SIGLEC7 (0.60) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL29361042 | 0.96 | SIGLEC7 (0.59) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL23346654 | 0.96 | SIGLEC7 (0.58) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL16491226 | 0.93 | SIGLEC7 (0.61) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL16449748 | 0.92 | SIGLEC7 (0.59) | SIGLEC7MAGSELLSELP | |
| SCHEMBL30913852 | 0.92 | SIGLEC7 (0.59) | SIGLEC7MAGSELLSELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564613-B2 | Strains having effects of preventing or treating cancers | GENOME AND COMPANY (KR) | 2026-03-03 | — | — | US | disclosed |
| US-12214004-B2 | Strains having effects of preventing or treating cancers | GENOME AND COMPANY (KR) | 2025-02-04 | — | — | US | disclosed |
| US-20210322490-A1 | NOVEL STRAINS HAVING EFFECTS OF PREVENTING OR TREATING CANCERS | GENOME AND COMPANY (KR) | 2021-10-21 | — | — | US | disclosed |
| US-20210138003-A1 | NOVEL STRAINS HAVING EFFECTS OF PREVENTING OR TREATING CANCERS | GENOME AND COMPANY (KR) | 2021-05-13 | — | — | US | disclosed |
| EP-3792343-A1 | NOVEL STRAIN HAVING PROPHYLACTIC OR THERAPEUTIC EFFECT ON CANCER | Genome and Company (KR) | 2021-03-17 | — | — | EP | disclosed |
| WO-2019216649-A9 | NOVEL STRAIN HAVING PROPHYLACTIC OR THERAPEUTIC EFFECT ON CANCER | 주식회사 지놈앤컴퍼니 (KR) | 2019-12-05 | — | — | WO | disclosed |
| WO-2019216649-A1 | NOVEL STRAIN HAVING PROPHYLACTIC OR THERAPEUTIC EFFECT ON CANCER | 주식회사 지놈앤컴퍼니 (KR) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210138003-A1 | NOVEL STRAINS HAVING EFFECTS OF PREVENTING OR TREATING CANCERS | LGALS3, MKI67, NGLY1 | SIGLEC7 1030/4885MAG 1359/4885SELL 2890/4885 |
| US-20210322490-A1 | NOVEL STRAINS HAVING EFFECTS OF PREVENTING OR TREATING CANCERS | LGALS3, MKI67, NGLY1 | SIGLEC7 1030/4885MAG 1359/4885SELL 2890/4885 |
| US-12214004-B2 | Strains having effects of preventing or treating cancers | LGALS3, B3GAT3, MKI67 | SIGLEC7 1039/4885MAG 1640/4885SELL 2459/4885 |
| US-12564613-B2 | Strains having effects of preventing or treating cancers | PDCD1, TOP1, CD274 | SIGLEC7 2152/4885MAG 2284/4885SELL 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.